Acrux Ltd (ASX: ACR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Acrux Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $21.22 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 290.72 million
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 63.64%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Acrux Ltd (ASX: ACR)
    Latest News

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Guess which ASX healthcare stock is rocketing 110% on US product launch

    Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

    Read more »

    A drawing of a rocket follows a chart up, indicating share price lift
    Share Gainers

    Why the Acrux (ASX:ACR) share price is rocketing 39% higher today

    The US FDA just gave this biotech the thumbs up...

    Read more »

    Share Market News

    ASX stock of the day: Acrux (ASX:ACR) shares soar 36% on FDA approval

    Acrux Limited (ASX: ACR) shares are soaring today after the pharma company gained a coveted FDA approval from the US…

    Read more »

    Healthcare Shares

    Why the Acrux share price skyrocketed 63% this morning

    The Acrux Limited (ASX: ACR) share price has taken off this morning, bolting out of the gates in response to a…

    Read more »

    a woman
    Share Fallers

    Insider share buying can't stop the Starpharma share price sliding again today

    The Starpharma Ltd (ASX:SPL) share price is falling again today after a shock FDA rejection.

    Read more »

    a woman
    Share Market News

    Are Mesoblast shares ready to shoot higher?

    Mesoblast limited (ASX:MSB) reported another quarter of significant cash outflows.

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares have started the week in the red

    The A2 Milk Company Ltd (ASX:A2M) share price is one of four starting the week in the red. Here's why...

    Read more »

    a woman
    Share Fallers

    Acrux Limited (ASX:ACR) shares crash lower on patent litigation

    The Acrux Limited (ASX:ACR) share price has crashed lower today after Valeant filed a patent litigation...

    Read more »

    a woman
    52-Week Highs

    Is it too late to buy these high-flying ASX shares?

    The ResApp Health Ltd (ASX:RAP) share price is one of three at a 52-week high or better today. Is it…

    Read more »

    a woman
    Share Gainers

    These 3 small caps are storming higher today

    The Money3 Corporation Limited (ASX:MNY) share price is one of three in the small cap space storming higher today...

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have dropped lower

    The Lynas Corporation Ltd (ASX:LYC) share price is one of four dropping lower on Thursday. Here's what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Is this the "Magic Formula" to investing in ASX shares?

    Joel Greenblatt's The Little Book That Still Beats the Market would have served investors very well over the past few…

    Read more »

    ACR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Acrux Ltd

    Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.

    ACR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.07 $0.00 0.00% 127,858 $0.07 $0.07 $0.07
    20 Jun 2024 $0.07 $0.00 0.00% 18,000 $0.07 $0.07 $0.07
    19 Jun 2024 $0.07 $0.00 0.00% 351,727 $0.08 $0.08 $0.07
    18 Jun 2024 $0.08 $0.00 0.00% 1,583 $0.08 $0.08 $0.08
    17 Jun 2024 $0.08 $0.00 0.00% 380,856 $0.08 $0.08 $0.08
    14 Jun 2024 $0.08 $0.00 0.00% 156,115 $0.08 $0.08 $0.08
    13 Jun 2024 $0.08 $0.00 0.00% 742,971 $0.09 $0.09 $0.08
    12 Jun 2024 $0.08 $0.00 0.00% 730,612 $0.08 $0.09 $0.08
    11 Jun 2024 $0.08 $0.00 0.00% 384,025 $0.08 $0.08 $0.08
    07 Jun 2024 $0.08 $0.00 0.00% 261,667 $0.08 $0.08 $0.08
    06 Jun 2024 $0.08 $0.00 0.00% 57,688 $0.08 $0.08 $0.08
    05 Jun 2024 $0.08 $0.00 0.00% 20,076 $0.08 $0.08 $0.08
    04 Jun 2024 $0.08 $0.00 0.00% 41,391 $0.08 $0.08 $0.08
    03 Jun 2024 $0.08 $0.00 0.00% 772,448 $0.08 $0.08 $0.08
    31 May 2024 $0.08 $0.00 0.00% 579,414 $0.08 $0.08 $0.08
    30 May 2024 $0.08 $0.01 14.71% 1,600,314 $0.07 $0.08 $0.07
    29 May 2024 $0.07 $0.00 0.00% 229,773 $0.07 $0.07 $0.07
    28 May 2024 $0.07 $0.00 0.00% 170,402 $0.07 $0.07 $0.07
    27 May 2024 $0.07 $0.00 0.00% 447,789 $0.07 $0.07 $0.07
    24 May 2024 $0.07 $0.00 0.00% 62,742 $0.07 $0.07 $0.07
    23 May 2024 $0.07 $0.00 0.00% 150,457 $0.07 $0.07 $0.07

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Mar 2024 Ross Dobinson Exercise 418,851 $23,036
    Conversion of securities.
    05 Mar 2024 Ross Dobinson Buy 418,851 $23,036
    Conversion of securities.
    05 Mar 2024 Donald Brumley Exercise 265,736 $14,615
    Conversion of securities. 797,210 Unlisted Rights
    20 Dec 2023 Geoffrey Brooke Exercise 138,187 $6,218
    Conversion of securities. 1,062,946 rights
    20 Dec 2023 Geoffrey Brooke Buy 138,187 $6,218
    Conversion of securities.
    20 Dec 2023 Timothy Oldham Buy 414,561 $18,655
    Conversion of securities.
    20 Dec 2023 Timothy Oldham Exercise 414,561 $18,655
    Conversion of securities. 1,062,946 unlisted rights
    05 Dec 2023 Timothy Oldham Issued 1,062,946 $52,084
    Issue of securities. 14,77,507 Rights
    05 Dec 2023 Ross Dobinson Issued 1,675,405 $82,094
    Issue of securities. 1,675,405 unlisted rights
    05 Dec 2023 Geoffrey Brooke Issued 1,062,946 $52,084
    Issue of securities. 12,01,133 Rights
    05 Dec 2023 Donald Brumley Issued 1,062,946 $52,084
    Issue of securities. 1,062,946 Unlisted Rights
    24 Nov 2023 Donald Brumley Exercise 138,187 $5,942
    Conversion of securities.
    24 Nov 2023 Donald Brumley Buy 138,187 $5,942
    Conversion of securities.
    24 Nov 2023 Ross Dobinson Buy 237,610 $10,217
    Conversion of securities.
    24 Nov 2023 Ross Dobinson Exercise 237,610 $10,217
    Conversion of securities.
    30 Aug 2023 Ross Dobinson Buy 237,610 $11,405
    Conversion of securities.
    30 Aug 2023 Ross Dobinson Exercise 237,610 $11,405
    Conversion of securities. 237,610 unlisted rights
    30 Aug 2023 Geoffrey Brooke Buy 138,187 $6,632
    Conversion of securities.
    30 Aug 2023 Geoffrey Brooke Exercise 138,187 $6,632
    Conversion of securities.
    30 Aug 2023 Donald Brumley Buy 138,187 $6,632
    Conversion of securities.
    30 Aug 2023 Donald Brumley Exercise 138,187 $6,632
    Conversion of securities. 138,187 Unlisted Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ross Dobinson Non-Executive ChairmanNon-Executive Director Jul 2012
    Mr Dobinson has been a Director since 1998, was appointed Chairman in January 2006 and then Executive Chairman from July 2012 to October 2014. He is a founder and former CEO of Acrux. Mr Dobinson has a background in investment banking and stockbroking.
    Dr Geoffrey E.D Brooke Non-Executive Director Jun 2016
    Mr Brooke joined the Board in June 2016. He founded GBS Venture Partners Pty Ltd in 1996 and has more than 20 years of venture capital experience. In January 2014, he reduced his involvement in GBS and is now special adviser to the firm and its funds. Mr Brooke was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Mr Brooke's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. Mr Brooke is licensed in clinical medicine by the Medical Board of Victoria, Australia and his postgraduate work was in anaesthetics and intensive care.
    Dr Timothy Oldham Non-Executive Director Oct 2013
    Mr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. Mr Oldham is the CEO and Managing Director at AdAlta Ltd (ASX: 1AD). AdAlta is a clinical stage biotech company developing an innovative range of new antibody-like drugs. Prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim leadership services and acquiring cell and gene therapy assets. He was previously CEO and Managing Director of Cell Therapies Pty Ltd and President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of generic pharmaceuticals, devices, biologics and cellular therapies. Mr Oldham began his business career as an engagement manager with McKinsey & Company.
    Mr Michael John Kotsanis Chief Executive OfficerManaging Director Nov 2014
    Mr Kotsanis is a seasoned executive with over 30 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based pharmaceutical company with global revenue over EUR250 million. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira and where he was responsible for delivering over US$500 million in annual revenue. Hospira was the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer. Mr Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Prior to Faulding, Mr Kotsanis held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11 year period.
    Mr Donald Charles Brumley Non-Executive Director Jun 2021
    Mr Brumley has 30 years' experience as a senior partner of Ernst & Young, Oceania. He has eexperience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Mr Brumley was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is a Fellow of Chartered Accountants Australia & New Zealand and is a member of the Australian Institute of Company Directors.
    Ms Joanna Johnson Chief Financial OfficerCompany Secretary Jun 2021
    -
    Joanna Johnson Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Phillip Asset Management Limited 31,847,134 11.05%
    Citicorp Nominees Pty Limited 4,831,059 1.68%
    Hishenk Pty Ltd 4,500,000 1.56%
    Dr Thomas Vui Chung Chai 4,460,560 1.55%
    Mr Ross Dobinson 4,355,174 1.51%
    Pacific Custodians Pty Limited 3,849,912 1.34%
    Ashwood River Pty Ltd 3,800,000 1.32%
    Ddh Graham Limited 3,682,818 1.28%
    Mr Paul Cozzi 3,259,121 1.13%
    Mr Christopher Murray Abbott 3,000,000 1.04%
    The Poole Family Superannuation Fund Pty Ltd 3,000,000 1.04%
    Mr Donald Charles Brumley 2,853,998 0.99%
    Tso Pty Ltd 2,625,734 0.91%
    Mr Alan Jebb & Mrs Sandra Jebb 2,430,707 0.84%
    Willoughby Capital Pty Ltd 2,300,000 0.80%
    Mr Ian Victor Lancini & Mrs Debra Ann Lancini 2,045,000 0.71%
    Mr Bikash Kaji Baniya 2,012,119 0.70%
    Adam Jamal 1,905,719 0.66%
    Durbin Superannuation Pty Ltd 1,727,640 0.60%
    Asia Union Investments Pty Limited 1,691,083 0.59%
    Hsbc Custody Nominees (Australia) Limited 1,657,801 0.58%
    Neweconomy Com Au Nominees Pty Limited 1,511,799 0.52%
    Mr Michael John Kotsanis 1,511,083 0.52%
    Mr David Andrew Slobom & Mrs Linda Jane Slobom 1,409,596 0.49%
    Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 1,319,986 0.46%
    Morgan Stanley Australia Securities (Nominee) Pty Limited 1,306,852 0.45%

    Profile

    since

    Note